Synthesis of the bicyclic core of tagetitoxin

Julien R. H. Plet and Michael J. Porter *
Department of Chemistry, University College London, Christopher Ingold Building, 20 Gordon Street, London, UK WC1H 0AJ. E-mail: m.j.porter@ucl.ac.uk; Fax: +44 20 7679 7463; Tel: +44 20 7679 4710

Received (in Cambridge, UK) 19th January 2006 , Accepted 31st January 2006

First published on 14th February 2006


Abstract

A synthesis of the 9-oxa-3-thiabicyclo[3.3.1]nonane ring system, which constitutes the core of the RNA polymerase inhibitor tagetitoxin, has been achieved through cyclisation of a thiol onto an electrophilic ketone.


Tagetitoxin is a phytotoxin which was isolated from the plant pathogenic bacterium Pseudomonas syringae pv. tagetis in 1981.1 The compound induces chlorosis in the apex of infected plants, an effect which has been traced to inhibition of RNA polymerase in chloroplasts.2 Furthermore, tagetitoxin inhibits bacterial RNA polymerase,2 and is the only natural product known to inhibit eukaryotic RNA polymerase III in a specific manner.3 Recently, a crystal structure of the RNA polymerase from Thermus thermophilus with tagetitoxin bound to the active site was published;4 consideration of this structure led the authors to postulate that tagetitoxin acts by stabilisation of an inactive intermediate in the transcription process.

The structure which was assigned to the compound shortly after its isolation5 was later rejected in favour of a bicyclic structure based on the 9-oxa-3-thiabicyclo[3.3.1]nonane ring system. Structure 1 was favoured, although the spectroscopic data did not rule out the closely related structure 2 (Fig. 1).6


Proposed structures of tagetitoxin.
Fig. 1 Proposed structures of tagetitoxin.

To date, limited work has been published detailing synthetic approaches to tagetitoxin and its analogues,7 and none has yet been successful in generating the bicyclic ring system. In this communication we describe a synthesis of this bicyclic core structure, starting from a carbohydrate precursor.

Our initial strategy focused on the use of a carbene-mediated ring expansion of 1,3-oxathiolanes.8D-Glucose was converted to the bicyclic monothioacetal 39 through displacement of an anomeric bromide and a 6-tosylate with potassium O-ethylxanthate (Scheme 1).10 Ring expansion was then attempted using ethyl diazo(triethylsilyl)acetate and catalytic rhodium(II) acetate;8 this led not to the anticipated bridged bicycle, but instead to glycal 5. This product may arise through sulfur ylid formation and heterolytic C–S bond cleavage to give zwitterion 4; rather than the desired C–C bond formation, this intermediate is presumed to undergo a ring-flip to the more stable conformer followed by proton transfer to afford the observed product.



          Reagents and conditions: i. TsCl, pyridine; Ac2O; ii. HBr, AcOH; iii. KSCSOEt, DMF, 50 °C (46% 3 over 3 steps) or KSCSOEt, acetone, reflux (47% 6 over 3 steps); iv. Et3SiC(N2)CO2Et, Rh2(OAc)4, benzene, reflux, 34%; v. NH3, MeOH, H2O, 50%; vi. tBu2SiCl2, Et3N, CH2Cl2, 86%; vii. Et3SiC(N2)CO2Et, Rh2(O2CC3F7)4, benzene, reflux, 21%.
Scheme 1 Reagents and conditions: i. TsCl, pyridine; Ac2O; ii. HBr, AcOH; iii. KSCSOEt, DMF, 50 °C (46% 3 over 3 steps) or KSCSOEt, acetone, reflux (47% 6 over 3 steps); iv. Et3SiC(N2)CO2Et, Rh2(OAc)4, benzene, reflux, 34%; v. NH3, MeOH, H2O, 50%; vi. tBu2SiCl2, Et3N, CH2Cl2, 86%; vii. Et3SiC(N2)CO2Et, Rh2(O2CC3F7)4, benzene, reflux, 21%.

To circumvent this difficulty, a conformationally constrained substrate was designed whose derived zwitterion (analogous to 4) would be incapable of ring-flipping. 3-Methyl-D-glucose was converted to bicycle 6, then the acetate groups were cleaved and a bridging di-tert-butylsilylene protecting group installed. Treatment of the resulting tricycle 7 with ethyl diazo(triethylsilyl)acetate in the presence of rhodium(II) heptafluorobutyrate gave a low yield of primary alcohol 9 as the only isolable product. In this case, the sulfur ylid 8 forms as required but this, rather than undergoing C–S bond heterolysis and ring expansion, is trapped by adventitious water to give the bicyclic alcohol 9.

Due to the failure of our initial approach to the tagetitoxin skeleton, a new strategy was adopted in which the 1,4-oxathiane ring of the natural product would be formed by cyclisation of a thiol onto an electron-deficient ketone, rather than through a carbene-mediated ring expansion.

Phenyl 1-thio-β-D-glucopyranoside (10) was converted to the fully protected analogue 1111 before NBS-promoted hydrolysis of the thioglycoside linkage (Scheme 2). Oxidation to the δ-lactone 12 was accomplished using Dess–Martin periodinane. Cerium-mediated addition of trimethylsilylacetylene followed by deoxygenation and desilylation then afforded terminal alkyne 14. Bromination to give 15 was followed by oxidation with potassium permanganate in aqueous methanol12 to yield α-ketoester 16.



          Reagents and conditions: i. TBDPS-Cl, imidazole, DMF, 99%; ii. BnBr, NaH, DMF, 87%; iii. NBS, aq. acetone, 95%; iv. Dess–Martin periodinane, pyridine, CH2Cl2, 69%; v. TMSCCH, n-BuLi, CeCl3·7H2O, THF, −78 °C to rt, 96%; vi. Et3SiH, TMSOTf, CH2Cl2, 74%; vii. NaOH, MeOH, CH2Cl2, 100%; viii. NBS, AgNO3, acetone, 98%; ix. KMnO4, NaHCO3, MgSO4, aq. MeOH, 84%; x. HF·py, THF, −78 °C to rt, 77%.
Scheme 2 Reagents and conditions: i. TBDPS-Cl, imidazole, DMF, 99%; ii. BnBr, NaH, DMF, 87%; iii. NBS, aq. acetone, 95%; iv. Dess–Martin periodinane, pyridine, CH2Cl2, 69%; v. TMSC[triple bond, length as m-dash]CH, n-BuLi, CeCl3·7H2O, THF, −78 °C to rt, 96%; vi. Et3SiH, TMSOTf, CH2Cl2, 74%; vii. NaOH, MeOH, CH2Cl2, 100%; viii. NBS, AgNO3, acetone, 98%; ix. KMnO4, NaHCO3, MgSO4, aq. MeOH, 84%; x. HF·py, THF, −78 °C to rt, 77%.

On cleavage of the silyl ether with TBAF, concomitant elimination of the 2-benzyloxy group (glucose numbering) to form an enol ether was observed. However, when silyl ether 16 was treated with HF–pyridine, the sole product was tricyclic acetal 17, in which not only the silyl ether but also the 3- and 4-benzyl ethers had been cleaved, and an acetal had formed between the ketone and the 3- and 6-OH groups.

Formation of the tricyclic acetal 17 precluded introduction of a sulfur atom at C6, but alteration of the order of steps allowed completion of the synthesis of the tagetitoxin skeleton; thus double desilylation of 13 could be achieved with TBAF to give primary alcohol 18 (Scheme 3). Activation as the mesylate was followed by displacement with potassium thioacetate, and bromination of the alkyne afforded 19. Oxidation as for compound 15 gave the α-ketoester 20, and removal of the S-acetyl protecting group using hydrazine hydrate in methanol led directly to the bicyclic hemithioacetal 21.



          Reagents and conditions: i. TBAF, THF, 99%; ii. MsCl, Et3N, DMAP, CH2Cl2, 95%; iii. KSAc, DMF, 99%; iv. NBS, AgNO3, acetone, 98%; v. KMnO4, NaHCO3, MgSO4, aq. MeOH, 71%; vi. N2H4·H2O, MeOH, 88%.
Scheme 3 Reagents and conditions: i. TBAF, THF, 99%; ii. MsCl, Et3N, DMAP, CH2Cl2, 95%; iii. KSAc, DMF, 99%; iv. NBS, AgNO3, acetone, 98%; v. KMnO4, NaHCO3, MgSO4, aq. MeOH, 71%; vi. N2H4·H2O, MeOH, 88%.

The structure of 21 was confirmed by mass spectrometry and NMR; in particular, an HMBC correlation was observed between the hemithioacetal carbon at 71.9 ppm and one of the CH2S protons at 1.57 ppm. Vicinal coupling constants of 9.3 and 9.6 Hz between the pairs of CHOBn protons indicated a boat conformation for the tetrahydropyran ring, as depicted in 21. The hemithioacetal was obtained as a single stereoisomer, although the configuration of this centre was not determined.

In conclusion, we have carried out the first synthesis of the tagetitoxin skeleton, by unmasking of a thiol in the presence of an electrophilic α-ketoester, triggering spontaneous cyclisation to a hemithioacetal. Efforts towards synthesis of the fully functionalised tagetitoxin structure are under way and will be reported in due course.

We thank EPSRC and UCL for financial support of this work.

Notes and references

  1. R. E. Mitchell and R. D. Durbin, Physiol. Plant Pathol., 1981, 18, 157–168 Search PubMed.
  2. D. E. Mathews and R. D. Durbin, J. Biol. Chem., 1990, 265, 493–498 CAS.
  3. T. H. Steinberg, D. E. Mathews, R. D. Durbin and R. R. Burgess, J. Biol. Chem., 1990, 265, 499–505 CAS ; for a recently identified specific inhibitor of RNA polymerase III, see L. P. Wu, J. Pan, V. Thoroddsen, D. R. Wysong, R. K. Blackman, C. E. Bulawa, A. E. Gould, T. D. Ocain, L. R. Dick, P. Errada, P. K. Dorr, T. Parkinson, T. Wood, D. Kornitzer, Z. Weissman, I. M. Willis and K. McGovern, Eukaryotic Cell, 2003, 2, 256–264 Search PubMed.
  4. D. G. Vassylyev, V. Svetlov, M. N. Vassylyeva, A. Perederina, N. Igarashi, N. Matsugaki, S. Wakatsuki and I. Artsimovitch, Nat. Struct. Mol. Biol., 2005, 12, 1086–1093 CrossRef CAS.
  5. R. E. Mitchell and R. D. Durbin, Phytochemistry, 1983, 22, 1425–1428 CrossRef CAS.
  6. R. E. Mitchell, J. M. Coddington and H. Young, Tetrahedron Lett., 1989, 30, 501–504 CrossRef CAS.
  7. (a) T. Sammakia, T. B. Hurley, D. M. Sammond, R. S. Smith, S. B. Sobolov and T. R. Oeschger, Tetrahedron Lett., 1996, 37, 4427–4430 CrossRef CAS; (b) B. R. Dent, R. H. Furneaux, G. J. Gainsford and G. P. Lynch, Tetrahedron, 1999, 55, 6977–6996 CrossRef CAS.
  8. (a) M. Ioannou, M. J. Porter and F. Saez, Chem. Commun., 2002, 346–347 RSC; (b) M. Ioannou, M. J. Porter and F. Saez, Tetrahedron, 2005, 61, 43–50 CrossRef CAS.
  9. H. Driguez, C. McAuliffe, R. V. Stick, D. M. Tilbrook and S. J. Wiliams, Aust. J. Chem., 1996, 49, 343–348 CrossRef CAS.
  10. (a) L. S. Jeong, R. F. Schinazi, J. W. Beach, H. O. Kim, S. Nampalli, K. Shanmuganathan, A. J. Alves, A. Mcmillan, C. K. Chu and R. Mathis, J. Med. Chem., 1993, 36, 181–195 CrossRef CAS; (b) L. S. Jeong, R. F. Schinazi, J. W. Beach, H. O. Kim, K. Shanmuganathan, S. Nampalli, M. W. Chun, W. K. Chung, B. G. Choi and C. K. Chu, J. Med. Chem., 1993, 36, 2627–2638 CrossRef CAS.
  11. M. Sasaki, K. Tachibana and H. Nakanishi, Tetrahedron Lett., 1991, 32, 6873–6876 CrossRef CAS.
  12. L. S. Li and Y. L. Wu, Tetrahedron Lett., 2002, 43, 2427–2430 CrossRef CAS.

Footnotes

Electronic supplementary information (ESI) available: HMQC and HMBC spectra for 21. See DOI: 10.1039/b600819d
Data for 21: [α]17D +3.1 (c 1.07 in EtOH); νmax/cm−1 (film) 3445 (OH), 2928 (CH), 1736 (C[double bond, length as m-dash]O); δH (500 MHz, C6D6) 7.38–6.99 (15H, m, ArH), 5.01 (1H, d, J 11.3), 4.92 (1H, d, J 11.3), 4.82 (1H, d, J 11.6), 4.75 (1H, d, J 11.6) and 4.65 (1H, d, J 12.0, 5 of PhCH2), 4.43 (1H, dd, J 9.3, 2.8, H-2), 4.39 (1H, J 12.0, 1 of PhCH2), 4.36 (1H, br d, J 2.8, H-1), 4.22 (1H, t, J 9.4, H-3), 4.19 (1H, td, J 3.6, 1.9, H-5), 4.11 (1H, s, OH), 4.03 (1H, dd, J 9.6, 3.7, H-4), 3.30 (1H, dd, J 13.4, 3.6, 1 of CH2S), 3.24 (3H, s, CH3), 1.57 (1H, br d, J 13.4, 1 of CH2S); δC (125 MHz, C6D6) 173.4 (C[double bond, length as m-dash]O), 139.1, 138.9 and 138.6 (3 × aromatic C), 82.2 (C-3), 80.0 (C-4), 79.8 (C-2), 79.5 (C-1), 75.0 (PhCH2), 73.3 (C-5), 73.2 (PhCH2), 72.4 (PhCH2), 71.9 (SCOH), 52.5 (OCH3), 40.9 (C-6), other aromatic carbons obscured by solvent; m/z (FAB+) 559 (MNa+, 2%), 326 (21), 199 (26), 176 (100); HRMS (FAB+) found 559.1784; C30H32O6SNa (MNa+) requires 559.1766.

This journal is © The Royal Society of Chemistry 2006
Click here to see how this site uses Cookies. View our privacy policy here.